Info

Aeolus Pharmaceuticals, Inc. is a biopharmaceutical company that is developing a class of catalytic antioxidant compounds for diseases and disorders of the central nervous system, respiratory system, autoimmune system and oncology. The Company’s initial target applications are for the side effects of mustard gas exposure, cancer radiation therapy and amyotrophic lateral sclerosis (ALS) or Lou Gehrig’s disease. Aeolus Pharmaceuticals, Inc. has reported positive safety results from two Phase I clinical trials of AEOL 10150, its principal drug candidate, with no serious adverse events noted. AEOL 10150 has been thoroughly tested for safety, tolerability and pharmacokinetics with no serious or clinically significant adverse effects observed. As of September 30, 2007, 37 patients had received AEOL 10150 in two clinical trials designed to test the safety and tolerability of the drug candidate.(Source: 10-K)